Anika Therapeutics (ANIK) Gross Margin (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Gross Margin data on file, last reported at 64.15% in Q1 2026.

• On a quarterly basis, Gross Margin rose 805.0% year-over-year to 64.15% in Q1 2026; TTM through Mar 2026 was 58.59%, a 266.0% decrease from a year earlier, with the FY2025 full-year figure at 56.56%, down 682.0% from the prior year.
• Gross Margin for Q1 2026 stood at 64.15%, up from 62.65% in the prior quarter.
• Over the last five years, Gross Margin for ANIK reached as high as 66.69% in Q2 2024 and fell as low as 199.14% in Q4 2023.
• Historically, Gross Margin has averaged 33.73% across 5 years, with a median of 60.16% in 2023.
• Across the five-year window, Gross Margin tumbled 18607 bps in 2022 and soared 25510 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 135.45% in 2022, then tumbled by 47 bps to 199.14% in 2023, then jumped by 128 bps to 55.96% in 2024, then rose by 12 bps to 62.65% in 2025, then increased by 2 bps to 64.15% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 64.15% in Q1 2026, 62.65% in Q4 2025, and 56.02% in Q3 2025.